Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
Globe Newswire (Tue, 7-Jul 7:00 AM ET)
Avalo Therapeutics to Join the Russell 2000 and Russell 3000 Indexes
Globe Newswire (Fri, 26-Jun 7:00 AM ET)
Avalo Therapeutics Appoints Ron Philip to Board of Directors
Globe Newswire (Tue, 23-Jun 7:00 AM ET)
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1 Antibody
Globe Newswire (Tue, 16-Jun 7:00 AM ET)
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 22-May 4:01 PM ET)
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Globe Newswire (Wed, 13-May 7:00 AM ET)
Market Chameleon (Wed, 6-May 5:54 AM ET)
Market Chameleon (Wed, 6-May 3:05 AM ET)
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
Globe Newswire (Tue, 5-May 11:33 PM ET)
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Globe Newswire (Tue, 5-May 4:05 PM ET)
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Avalo Therapeutics trades on the NASDAQ stock market under the symbol AVTX.
As of July 14, 2026, AVTX stock price declined to $18.89 with 218,686 million shares trading.
AVTX has a beta of 1.43, meaning it tends to be more sensitive to market movements. AVTX has a correlation of 0.03 to the broad based SPY ETF.
AVTX has a market cap of $992.96 million. This is considered a Small Cap stock.
In the last 3 years, AVTX traded as high as $84.79 and as low as $3.39.
The top ETF exchange traded funds that AVTX belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
AVTX has outperformed the market in the last year with a return of +295.2%, while the SPY ETF gained +21.7%. In the last 3 month period, AVTX beat the market returning +41.6%, while SPY returned +9.8%. However, in the most recent 2 weeks AVTX has underperformed the stock market by returning -2.1%, while SPY returned +1.4%.
AVTX support price is $17.85 and resistance is $19.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVTX shares will trade within this expected range on the day.
